News Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer Staff September 11, 2023 Iframe sync Post navigation Previous: EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023Next: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference More Stories Healthcare News TempraMed Enters Strategic Media Partnership with Dr. Phil’s Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States Staff February 2, 2026 Healthcare News Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth Staff February 1, 2026 Healthcare News Patient Care AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai Staff February 1, 2026
